Bioinformatics for cancer immunotherapy target discovery

Cancer Immunology, Immunotherapy

Volumn 63, Issue 12, 2014, Pages 1235-1249

  Olsen, Lars Rønn ^a,b,c   Campos, Benito ^d   Barnkob, Mike Stein ^e   Winther, Ole ^a,f   Brusic, Vladimir ^c,g   Andersen, Mads Hald ^h  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^e ODENSE UNIVERSITY HOSPITAL   (Denmark)

^f TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^g NAZARBAYEV UNIVERSITY   (Kazakhstan)

^h GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Biological databases; Cancer vaccines; Computational biology; T cell epitopes; Tumor antigens

Indexed keywords

CANCER ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITOPE; MESSENGER RNA; T LYMPHOCYTE ANTIGEN; TUMOR ANTIGEN;

ANTIGEN EXPRESSION; BIOINFORMATICS; CANCER IMMUNOTHERAPY; CANCER SCREENING; COMPUTER ANALYSIS; COMPUTER MODEL; COMPUTER PROGRAM; CROSS REFERENCING EXPRESSION; DATA BASE; DOCUMENTATION; DRUG TARGETING; GENE EXPRESSION; HLA SYSTEM; HUMAN; IMMUNE SYSTEM; IMMUNOGENICITY; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; REVIEW; T LYMPHOCYTE; TUMOR GENE; BIOLOGY; DRUG DEVELOPMENT; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS; PROCEDURES;

COMPUTATIONAL BIOLOGY; DRUG DISCOVERY; HUMANS; IMMUNOTHERAPY; NEOPLASMS;

EID: 84916598431     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-014-1627-7     Document Type: Review

References (147)

1. Kirkwood JM, Butterfield LH, Tarhini AA et al (2012) Immunotherapy of cancer in 2012. CA Cancer J Clin 62:309–335. doi:10.3322/caac.20132
2. Rees R, Laversin S, Murray C, Ball G (2012) Current approaches to identify and evaluate cancer biomarkers for patient stratification. In: Morrow WJW, Sheikh NA, Schmidt CS, Davies DH (eds) Vaccinology: principles and Practice. Wiley, Oxford, pp 452–463
3. Wei W-Z, Morris GP, Kong Y-CM (2004) Anti-tumor immunity and autoimmunity: a balancing act of regulatory T cells. Cancer Immunol Immunother 53:73–78. doi:10.1007/s00262-003-0444-1
4. Blades RA, Keating PJ, McWilliam LJ et al (1995) Loss of HLA class I expression in prostate cancer: implications for immunotherapy. Urology 46:681–686. doi:10.1016/S0090-4295(99)80301-X (discussion 686–7)
5. Curiel TJ, Coukos G, Zou L et al (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942–949. doi:10.1038/nm1093
6. Gabrilovich DI, Nagaraj S (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9:162–174. doi:10.1038/nri2506
7. Prendergast GC (2008) Immune escape as a fundamental trait of cancer: focus on IDO. Oncogene 27:3889–3900. doi:10.1038/onc.2008.35
8. Bronte V, Serafini P, De Santo C et al (2003) IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. J Immunol 170:270–278
9. Ben-Baruch A (2006) Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators. Semin Cancer Biol 16:38–52
10. Wang T, Niu G, Kortylewski M et al (2004) Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 10:48–54. doi:10.1038/nm976
11. Latchman Y, Wood CR, Chernova T et al (2001) PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2:261–268. doi:10.1038/85330
12. Falk K, Rötzschke O, Stevanović S et al (1991) Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 351:290–296. doi:10.1038/351290a0
13. Reinherz EL, Tan K, Tang L et al (1999) The crystal structure of a T cell receptor in complex with peptide and MHC class II. Science 286:1913–1921
14. Rock KL, Gramm C, Rothstein L et al (1994) Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 78:761–771
15. Androlewicz MJ, Anderson KS, Cresswell P (1993) Evidence that transporters associated with antigen processing translocate a major histocompatibility complex class I-binding peptide into the endoplasmic reticulum in an ATP-dependent manner. Proc Natl Acad Sci USA 90:9130–9134
16. Henney CS, Gaffney J, Bloom BR (1974) On the relation of products of activated lymphocytes to cell-mediated cytolysis. J Exp Med 140:837–852
17. Van der Bruggen P, Traversari C, Chomez P et al (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254:1643–1647. doi:10.1126/science.1840703
18. Boon T, van der Bruggen P (1996) Human tumor antigens recognized by T lymphocytes. J Exp Med 183:725–729
19. Van den Eynde BJ, van der Bruggen P (1997) T cell defined tumor antigens. Curr Opin Immunol 9:684–693
20. Cheever MA, Allison JP, Ferris AS et al (2009) The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 15:5323–5337. doi:10.1158/1078-0432.CCR-09-0737
21. Novellino L, Castelli C, Parmiani G (2005) A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother 54:187–207. doi:10.1007/s00262-004-0560-6
22. Seremet T, Brasseur F, Coulie PG (2011) Tumor-specific antigens and immunologic adjuvants in cancer immunotherapy. Cancer J 17:325–330. doi:10.1097/PPO.0b013e3182326004
23. Lurquin C, Van Pel A, Mariamé B et al (1989) Structure of the gene of tum- transplantation antigen P91A: the mutated exon encodes a peptide recognized with Ld by cytolytic T cells. Cell 58:293–303
24. Mariuzza RA, Phillips SE, Poljak RJ (1987) The structural basis of antigen-antibody recognition. Annu Rev Biophys Biophys Chem 16:139–159. doi:10.1146/annurev.bb.16.060187.001035
25. Dunn GP, Bruce AT, Ikeda H et al (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3:991–998. doi:10.1038/ni1102-991
26. Rappuoli R (2000) Reverse vaccinology. Curr Opin Microbiol 3:445–450
27. Harndahl M, Rasmussen M, Roder G et al (2012) Peptide-MHC class I stability is a better predictor than peptide affinity of CTL immunogenicity. Eur J Immunol 42:1405–1416. doi:10.1002/eji.201141774
28. Rudolph MG, Stanfield RL, Wilson IA (2006) How TCRs bind MHCs, peptides, and coreceptors. Annu Rev Immunol 24:419–466. doi:10.1146/annurev.immunol.23.021704.115658
29. Dhanasekaran SM, Barrette TR, Ghosh D et al (2001) Delineation of prognostic biomarkers in prostate cancer. Nature 412:822–826. doi:10.1038/35090585
30. Spentzos D, Levine DA, Ramoni MF et al (2004) Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J Clin Oncol 22:4700–4710. doi:10.1200/JCO.2004.04.070
31. Buyse M, Loi S, van’t Veer L et al (2006) Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 98:1183–1192. doi:10.1093/jnci/djj329
32. Verhaak RGW, Hoadley KA, Purdom E et al (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98–110. doi:10.1016/j.ccr.2009.12.020
33. Snuderl M, Fazlollahi L, Le LP et al (2011) Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell 20:810–817. doi:10.1016/j.ccr.2011.11.005
34. Sottoriva A, Spiteri I, Piccirillo SGM et al (2013) Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci USA 110:4009–4014. doi:10.1073/pnas.1219747110
35. Campoli M, Chang C-C, Ferrone S (2002) HLA class I antigen loss, tumor immune escape and immune selection. Vaccine 20(Suppl 4):A40–A45
36. Chang C-C, Campoli M, Restifo NP et al (2005) Immune selection of hot-spot beta 2-microglobulin gene mutations, HLA-A2 allospecificity loss, and antigen-processing machinery component down-regulation in melanoma cells derived from recurrent metastases following immunotherapy. J Immunol 174:1462–1471
37. Sioud M, Hansen M, Dybwad A (2000) Profiling the immune responses in patient sera with peptide and cDNA display libraries. Int J Mol Med 6:123–128
38. Hanash S (2003) Disease proteomics. Nature 422:226–232. doi:10.1038/nature01514
39. Loging WT, Lal A, Siu IM et al (2000) Identifying potential tumor markers and antigens by database mining and rapid expression screening. Genome Res 10:1393–1402
40. Scanlan MJ, Gordon CM, Williamson B et al (2002) Identification of cancer/testis genes by database mining and mRNA expression analysis. Int J Cancer 98:485–492
41. Ramsay G (1998) DNA chips: state-of-the art. Nat Biotechnol 16:40–44. doi:10.1038/nbt0198-40
42. Wang Z, Gerstein M, Snyder M (2009) RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet 10:57–63. doi:10.1038/nrg2484
43. Gentleman RC, Carey VJ, Bates DM et al (2004) Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 5:R80. doi:10.1186/gb-2004-5-10-r80
44. Irizarry RA, Hobbs B, Collin F et al (2003) Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4:249–264. doi:10.1093/biostatistics/4.2.249
45. Smyth GK (2004) Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3:Article3. doi: 10.2202/1544-6115.1027
46. Perez-Llamas C, Lopez-Bigas N (2011) Gitools: analysis and visualisation of genomic data using interactive heat-maps. PLoS ONE 6:e19541. doi:10.1371/journal.pone.0019541
47. Chatterjee M, Draghici S, Tainsky MA (2006) Immunotheranostics: breaking tolerance in immunotherapy using tumor autoantigens identified on protein microarrays. Curr Opin Drug Discov Dev 9:380–385
48. Miller JC, Zhou H, Kwekel J et al (2003) Antibody microarray profiling of human prostate cancer sera: antibody screening and identification of potential biomarkers. Proteomics 3:56–63. doi:10.1002/pmic.200390009
49. Hanash SM, Pitteri SJ, Faca VM (2008) Mining the plasma proteome for cancer biomarkers. Nature 452:571–579. doi:10.1038/nature06916
50. Bendall SC, Simonds EF, Qiu P et al (2011) Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. Science 332:687–696. doi:10.1126/science.1198704
51. Imielinski M, Cha S, Rejtar T et al (2012) Integrated proteomic, transcriptomic, and biological network analysis of breast carcinoma reveals molecular features of tumorigenesis and clinical relapse. Mol Cell Proteomics 11(M111):014910. doi:10.1074/mcp.M111.014910
52. Nilsson T, Mann M, Aebersold R et al (2010) Mass spectrometry in high-throughput proteomics: ready for the big time. Nat Methods 7:681–685. doi:10.1038/nmeth0910-681
53. Barrett T, Wilhite SE, Ledoux P et al (2013) NCBI GEO: archive for functional genomics data sets—update. Nucleic Acids Res 41:D991–D995. doi:10.1093/nar/gks1193
54. Brazma A, Hingamp P, Quackenbush J et al (2001) Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat Genet 29:365–371. doi:10.1038/ng1201-365
55. Rhodes DR, Kalyana-Sundaram S, Mahavisno V et al (2007) Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia 9:166–180
56. Bagger FO, Rapin N, Theilgaard-Mönch K et al (2013) HemaExplorer: a database of mRNA expression profiles in normal and malignant haematopoiesis. Nucleic Acids Res 41:D1034–D1039. doi:10.1093/nar/gks1021
57. Bagger FO, Rapin N, Theilgaard-Mönch K et al (2012) HemaExplorer: a Web server for easy and fast visualization of gene expression in normal and malignant hematopoiesis. Blood 119:6394–6395. doi:10.1182/blood-2012-05-427310
58. Gry M, Rimini R, Strömberg S et al (2009) Correlations between RNA and protein expression profiles in 23 human cell lines. BMC Genom 10:365. doi:10.1186/1471-2164-10-365
59. Uhlen M, Oksvold P, Fagerberg L et al (2010) Towards a knowledge-based human protein atlas. Nat Biotechnol 28:1248–1250. doi:10.1038/nbt1210-1248
60. Fernández-Suárez XM, Galperin MY (2013) The 2013 nucleic acids research database issue and the online molecular biology database collection. Nucleic Acids Res 41:D1–D7. doi:10.1093/nar/gks1297
61. Vigneron N, Stroobant V, Van den Eynde BJ, van der Bruggen P (2013) Database of T cell-defined human tumor antigens: the 2013 update. Cancer Immun 13:15
62. Almeida LG, Sakabe NJ, deOliveira AR et al (2009) CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens. Nucleic Acids Res 37:D816–D819. doi:10.1093/nar/gkn673
63. Slamon DJ, Clark GM, Wong SG et al (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177–182
64. Allred DC, Clark GM, Molina R et al (1992) Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol 23:974–979
65. Fisk B, Blevins TL, Wharton JT, Ioannides CG (1995) Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 181:2109–2117
66. Carter P, Presta L, Gorman CM et al (1992) Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 89:4285–4289
67. Rustici G, Kolesnikov N, Brandizi M et al (2013) ArrayExpress update—trends in database growth and links to data analysis tools. Nucleic Acids Res 41:D987–D990. doi:10.1093/nar/gks1174
68. Amberger J, Bocchini CA, Scott AF, Hamosh A (2009) McKusick’s online Mendelian inheritance in man (OMIM). Nucleic Acids Res 37:D793–D796. doi:10.1093/nar/gkn665
69. Flicek P, Ahmed I, Amode MR et al (2013) Ensembl 2013. Nucleic Acids Res 41:D48–D55. doi:10.1093/nar/gks1236
70. Safran M, Dalah I, Alexander J et al (2010) GeneCards version 3: the human gene integrator. database (Oxford) baq020. doi: 10.1093/database/baq020
71. Benson DA, Cavanaugh M, Clark K et al (2013) GenBank. Nucleic Acids Res 41:D36–D42. doi:10.1093/nar/gks1195
72. The UniProt Consortium (2013) Update on activities at the Universal Protein Resource (UniProt) in 2013. Nucleic Acids Res 41:D43–D47. doi:10.1093/nar/gks1068
73. Forbes SA, Bindal N, Bamford S et al (2011) COSMIC: mining complete cancer genomes in the catalogue of somatic mutations in cancer. Nucleic Acids Res 39:D945–D950. doi:10.1093/nar/gkq929
74. Holzhütter HG, Kloetzel PM (2000) A kinetic model of vertebrate 20S proteasome accounting for the generation of major proteolytic fragments from oligomeric peptide substrates. Biophys J 79:1196–1205. doi:10.1016/S0006-3495(00)76374-0
75. Kuttler C, Nussbaum AK, Dick TP et al (2000) An algorithm for the prediction of proteasomal cleavages. J Mol Biol 298:417–429. doi:10.1006/jmbi.2000.3683
76. Keşmir C, Nussbaum AK, Schild H et al (2002) Prediction of proteasome cleavage motifs by neural networks. Protein Eng 15:287–296
77. Peters B, Bulik S, Tampe R et al (2003) Identifying MHC class I epitopes by predicting the TAP transport efficiency of epitope precursors. J Immunol 171:1741–1749
78. Zhang GL, Petrovsky N, Kwoh CK et al (2006) PRED(TAP): a system for prediction of peptide binding to the human transporter associated with antigen processing. Immunome Res 2:3. doi:10.1186/1745-7580-2-3
79. Bhasin M, Lata S, Raghava GPS (2007) TAPPred prediction of TAP-binding peptides in antigens. Methods Mol Biol 409:381–386. doi:10.1007/978-1-60327-118-9_28
80. Saxová P, Buus S, Brunak S, Keşmir C (2003) Predicting proteasomal cleavage sites: a comparison of available methods. Int Immunol 15:781–787
81. Zhang GL, Ansari HR, Bradley P et al (2011) Machine learning competition in immunology—prediction of HLA class I binding peptides. J Immunol Methods 374:1–4. doi:10.1016/j.jim.2011.09.010
82. Lin HH, Ray S, Tongchusak S et al (2008) Evaluation of MHC class I peptide binding prediction servers: applications for vaccine research. BMC Immunol 9:8. doi:10.1186/1471-2172-9-8
83. Lin HH, Zhang GL, Tongchusak S et al (2008) Evaluation of MHC-II peptide binding prediction servers: applications for vaccine research. BMC Bioinform 9(Suppl 12):S22. doi:10.1186/1471-2105-9-S12-S22
84. Lundegaard C, Lund O, Nielsen M (2008) Accurate approximation method for prediction of class I MHC affinities for peptides of length 8, 10 and 11 using prediction tools trained on 9mers. Bioinformatics 24:1397–1398. doi:10.1093/bioinformatics/btn128
85. Nielsen M, Lund O (2009) NN-align. An artificial neural network-based alignment algorithm for MHC class II peptide binding prediction. BMC Bioinform 10:296. doi:10.1186/1471-2105-10-296
86. Parker KC, Bednarek MA, Coligan JE (1994) Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 152:163–175
87. Schuler MM, Nastke M-D, Stevanovikć S (2007) SYFPEITHI: database for searching and T-cell epitope prediction. Methods Mol Biol 409:75–93
88. Hu X, Mamitsuka H, Zhu S (2011) Ensemble approaches for improving HLA class I-peptide binding prediction. J Immunol Methods 374:47–52. doi:10.1016/j.jim.2010.09.007
89. Huang JC, Jojic N (2011) Modeling major histocompatibility complex binding by nonparametric averaging of multiple predictors and sequence encodings. J Immunol Methods 374:35–42. doi:10.1016/j.jim.2010.10.001
90. Nielsen M, Lundegaard C, Blicher T et al (2007) NetMHCpan, a method for quantitative predictions of peptide binding to any HLA-A and -B locus protein of known sequence. PLoS ONE 2:e796. doi:10.1371/journal.pone.0000796
91. Larsen MV, Lundegaard C, Lamberth K et al (2007) Large-scale validation of methods for cytotoxic T-lymphocyte epitope prediction. BMC Bioinform 8:424. doi:10.1186/1471-2105-8-424
92. Frankild S, de Boer RJ, Lund O et al (2008) Amino acid similarity accounts for T cell cross-reactivity and for “holes” in the T cell repertoire. PLoS ONE 3:e1831. doi:10.1371/journal.pone.0001831
93. Pierce BG, Weng Z (2013) A flexible docking approach for prediction of T cell receptor–peptide–MHC complexes. Protein Sci 22:35–46. doi:10.1002/pro.2181
94. Tung C-W, Ziehm M, Kämper A et al (2011) POPISK: T-cell reactivity prediction using support vector machines and string kernels. BMC Bioinform 12:446. doi:10.1186/1471-2105-12-446
95. Saethang T, Hirose O, Kimkong I et al (2013) PAAQD: predicting immunogenicity of MHC class I binding peptides using amino acid pairwise contact potentials and quantum topological molecular similarity descriptors. J Immunol Methods 387:293–302. doi:10.1016/j.jim.2012.09.016
96. Olsen LR, Zhang GL, Keskin DB et al (2011) Conservation analysis of dengue virus T-cell epitope-based vaccine candidates using peptide block entropy. Front Immunol 2:69. doi:10.3389/fimmu.2011.00069
97. Rongcun Y, Salazar-Onfray F, Charo J et al (1999) Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas. J Immunol 163:1037–1044
98. Reinhold B, Keskin DB, Reinherz EL (2010) Molecular detection of targeted major histocompatibility complex I-bound peptides using a probabilistic measure and nanospray MS(3) on a hybrid quadrupole-linear ion trap. Anal Chem 82:9090–9099. doi:10.1021/ac102387t
99. Andersen RS, Kvistborg P, Frøsig TM et al (2012) Parallel detection of antigen-specific T cell responses by combinatorial encoding of MHC multimers. Nat Protoc 7:891–902. doi:10.1038/nprot.2012.037
100. Erlich H (2012) HLA DNA typing: past, present, and future. Tissue Antigens 80:1–11. doi:10.1111/j.1399-0039.2012.01881.x
101. Sette A, Sidney J (1998) HLA supertypes and supermotifs: a functional perspective on HLA polymorphism. Curr Opin Immunol 10:478–482
102. Sette A, Sidney J (1999) Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism. Immunogenetics 50:201–212
103. Robinson J, Halliwell JA, McWilliam H et al (2013) The IMGT/HLA database. Nucleic Acids Res 41:D1222–D1227. doi:10.1093/nar/gks949
104. Helmberg W, Dunivin R, Feolo M (2004) The sequencing-based typing tool of dbMHC: typing highly polymorphic gene sequences. Nucleic Acids Res 32:W173–W175. doi:10.1093/nar/gkh424
105. Gonzalez-Galarza FF, Christmas S, Middleton D, Jones AR (2011) Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations. Nucleic Acids Res 39:D913–D919. doi:10.1093/nar/gkq1128
106. Helmberg W (2012) Bioinformatic databases and resources in the public domain to aid HLA research. Tissue Antigens 80:295–304. doi:10.1111/tan.12000
107. Hildesheim A, Apple RJ, Chen C-J et al (2002) Association of HLA class I and II alleles and extended haplotypes with nasopharyngeal carcinoma in Taiwan. J Natl Cancer Inst 94:1780–1789
108. Wang C, Krishnakumar S, Wilhelmy J et al (2012) High-throughput, high-fidelity HLA genotyping with deep sequencing. Proc Natl Acad Sci USA 109:8676–8681. doi:10.1073/pnas.1206614109
109. Boegel S, Löwer M, Schäfer M et al (2013) HLA typing from RNA-Seq sequence reads. Genome Med 4:102. doi:10.1186/gm403
110. Zhang GL, Keskin DB, Reinherz EL, Brusic V (2011) A cDNA microarray for rapid and economical identification of HLA profiles of individuals. In: IEEE international conference on bioinformatics and biomedical work, pp 677–679
111. Pabinger S, Dander A, Fischer M et al (2014) A survey of tools for variant analysis of next-generation genome sequencing data. Brief Bioinform 15:256–278. doi:10.1093/bib/bbs086
112. Buggert M, Norström MM, Czarnecki C et al (2012) Characterization of HIV-specific CD4+ T cell responses against peptides selected with broad population and pathogen coverage. PLoS ONE 7:e39874. doi:10.1371/journal.pone.0039874
113. Bui H-H, Sidney J, Dinh K et al (2006) Predicting population coverage of T-cell epitope-based diagnostics and vaccines. BMC Bioinform 7:153. doi:10.1186/1471-2105-7-153
114. Warren RL, Choe G, Freeman DJ et al (2012) Derivation of HLA types from shotgun sequence datasets. Genome Med 4:95. doi:10.1186/gm396
115. Kim HJ, Pourmand N (2013) HLA haplotyping from RNA-seq data using hierarchical read weighting. PLoS ONE 8:e67885. doi:10.1371/journal.pone.0067885
116. Lundegaard C, Lamberth K, Harndahl M et al (2008) NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11. Nucleic Acids Res 36:W509–W512. doi:10.1093/nar/gkn202
117. Thompson JD, Gibson TJ, Higgins DG (2002) Multiple sequence alignment using ClustalW and ClustalX. Curr Protoc Bioinform Chapter 2:Unit 2.3. doi: 10.1002/0471250953.bi0203s00
118. Katoh K, Standley DM (2013) MAFFT multiple sequence alignment software version 7: improvements in performance and usability. Mol Biol Evol 30:772–780. doi:10.1093/molbev/mst010
119. Edgar RC (2004) MUSCLE: a multiple sequence alignment method with reduced time and space complexity. BMC Bioinform 5:113. doi:10.1186/1471-2105-5-113
120. Bui H-H, Sidney J, Li W et al (2007) Development of an epitope conservancy analysis tool to facilitate the design of epitope-based diagnostics and vaccines. BMC Bioinform 8:361. doi:10.1186/1471-2105-8-361
121. Olsen LR, Kudahl UJ, Simon C et al (2013) BlockLogo: visualization of peptide and sequence motif conservation. J Immunol Methods 400–401:37–44. doi:10.1016/j.jim.2013.08.014
122. Kawashima I, Hudson SJ, Tsai V et al (1998) The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. Hum Immunol 59:1–14
123. Forbes SA, Bhamra G, Bamford S et al (2008) The catalogue of somatic mutations in cancer (COSMIC). Curr Protoc Hum Genet Chapter 10:Unit 10.11. doi: 10.1002/0471142905.hg1011s57
124. Firth HV, Richards SM, Bevan AP et al (2009) DECIPHER: database of chromosomal imbalance and phenotype in humans using ensembl resources. Am J Hum Genet 84:524–533. doi:10.1016/j.ajhg.2009.03.010
125. Magrane M (2011) UniProt knowledgebase: a hub of integrated protein data. Database (Oxford) bar009. doi: 10.1093/database/bar009
126. Andersen MH, Becker JC, Thor Straten P (2005) Regulators of apoptosis: suitable targets for immune therapy of cancer. Nat Rev Drug Discov 4:399–409. doi:10.1038/nrd1717
127. Lee MJ, Ye AS, Gardino AK et al (2012) Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. Cell 149:780–794. doi:10.1016/j.cell.2012.03.031
128. Liu J, Ewald BA, Lynch DM et al (2006) Modulation of DNA vaccine-elicited CD8+ T-lymphocyte epitope immunodominance hierarchies. J Virol 80:11991–11997. doi:10.1128/JVI.01348-06
129. Ranieri E, Kierstead LS, Zarour H et al (2000) Dendritic cell/peptide cancer vaccines: clinical responsiveness and epitope spreading. Immunol Investig 29:121–125
130. Henderson RA, Finn OJ (1996) Human tumor antigens are ready to fly. Adv Immunol 62:217–256
131. Reid A, Vidal L, Shaw H, de Bono J (2007) Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu). Eur J Cancer 43:481–489. doi:10.1016/j.ejca.2006.11.007
132. Franceschini A, Szklarczyk D, Frankild S et al (2013) STRING v9.1: protein–protein interaction networks, with increased coverage and integration. Nucleic Acids Res 41:D808–D815. doi:10.1093/nar/gks1094
133. Kawaguchi Y, Kono K, Mimura K et al (2007) Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma. Br J Cancer 97:494–501. doi:10.1038/sj.bjc.6603885
134. Gutierrez C, Schiff R (2011) HER2: biology, detection, and clinical implications. Arch Pathol Lab Med 135:55–62. doi:10.1043/2010-0454-RAR.1
135. Subramanian A, Tamayo P, Mootha VK et al (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102:15545–15550. doi:10.1073/pnas.0506580102
136. Chatr-Aryamontri A, Breitkreutz B-J, Heinicke S et al (2013) The BioGRID interaction database: 2013 update. Nucleic Acids Res 41:D816–D823. doi:10.1093/nar/gks1158
137. Kanehisa M, Goto S (2000) KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res 28:27–30
138. Croft D, O’Kelly G, Wu G et al (2011) Reactome: a database of reactions, pathways and biological processes. Nucleic Acids Res 39:D691–D697. doi:10.1093/nar/gkq1018
139. Caoili SEC (2010) Benchmarking B-cell epitope prediction for the design of peptide-based vaccines: problems and prospects. J Biomed Biotechnol 2010:910524. doi:10.1155/2010/910524
140. Adams GP, Weiner LM (2005) Monoclonal antibody therapy of cancer. Nat Biotechnol 23:1147–1157. doi:10.1038/nbt1137
141. Porter DL, Levine BL, Kalos M et al (2011) Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365:725–733. doi:10.1056/NEJMoa1103849
142. El-Manzalawy Y, Honavar V (2010) Recent advances in B-cell epitope prediction methods. Immunome Res 6(Suppl 2):S2. doi:10.1186/1745-7580-6-S2-S2
143. Möller S, Croning MD, Apweiler R (2001) Evaluation of methods for the prediction of membrane spanning regions. Bioinformatics 17:646–653
144. Gajewski TF (2011) Molecular profiling of melanoma and the evolution of patient-specific therapy. Semin Oncol 38:236–242. doi:10.1053/j.seminoncol.2011.01.004
145. Galon J, Franck P, Marincola FM et al (2012) Cancer classification using the Immunoscore: a worldwide task force. J Transl Med 10:205. doi:10.1186/1479-5876-10-205
146. Galon J, Pagès F, Marincola FM et al (2012) The immune score as a new possible approach for the classification of cancer. J Transl Med 10:1. doi:10.1186/1479-5876-10-1
147. Pagès F, Kirilovsky A, Mlecnik B et al (2009) In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol 27:5944–5951. doi:10.1200/JCO.2008.19.6147